| Literature DB >> 35684459 |
Huanyu Guan1, Pengfei Li2, Qian Wang1, Fanli Zeng1, Daoping Wang1,3, Mei Zhou1,3, Meng Zhou1, Xun He1, Shanggao Liao1, Weidong Pan1,3.
Abstract
Polygonum capitatum as an ethnic medicine has been used to treat urinary tract infections, pyelonephritis and urinary calculi. In our previous study, P. capitatum was found to have anti-hyperuricemia effects. Nevertheless, the active constituents of P. capitatum for treating hyperuricemia were still unclear. In this study, an ultra-high-performance liquid chromatography coupled to quadrupole/orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap HRMS) was used to comprehensively detect the chemical ingredients of P. capitatum and its absorbed constituents in the plasma of hyperuricemia rats for the first time. Xcalibur 3.0 and Compound Discoverer 2.0 software coupled to mzCloud and ChemSpider databases were utilized for qualitative analysis. A total of 114 chemical components including phenolics, flavonoids, tannins, phenylpropanoids, amino acids, amides and others were identified or tentatively characterized based on the exact mass, retention time and structural information. Compared to the previous P. capitatum study, an additional 66 different components were detected. Moreover, 68 related xenobiotics including 16 prototype components and 52 metabolites were found in the plasma of hyperuricemia rats. The metabolic pathways included ring fission, hydrolysis, decarboxylation, dehydroxylation, methylation, glucuronidation and sulfation. This work may provide important information for further investigation on the active constituents of P. capitatum and their action mechanisms for anti-hyperuricemia effects.Entities:
Keywords: Polygonum capitatum; UHPLC-Q-Orbitrap HRMS; chemical profiling; metabolites
Mesh:
Substances:
Year: 2022 PMID: 35684459 PMCID: PMC9182448 DOI: 10.3390/molecules27113521
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1The TIC chromatograms of P. capitatum extract in negative (NEG) and positive (POS) ion modes.
Figure 2The proposed mass fragmentation pathway of compound 97.
Figure 3The fragmentation patterns of compounds 84 (A), 110 (B) and 77 (C).
Figure 4The fragmentation pathways of compounds 25 or 32 (A), 64 (B) and 33 (C). The dotted purple and green lines represent the cleavage positions of compound 33 in MS2 spectrum.
Figure 5The fragmentation patterns of compounds 96, 101 (A) and 106 (B).
The metabolites of P. capitatum in hyperuricemia rat plasma.
| Peak No. | Compounds | Molecular Formula | tR | Ion Mode | Precursor Ion | Error (ppm) | Product Ions |
|---|---|---|---|---|---|---|---|
| M1 | Gallic acid glucuronide | C13H14O11 | 1.93 | negative mode | 345.0464 | 3.25 | 169.0132 |
| M2 | 4- | C14H16O11 | 1.93 | negative mode | 359.0620 | 2.96 | 183.0292, 168.0068, 124.0154 |
| M3 | Gallic acid sulfate | C7H6O8S | 2.13 | negative mode | 248.9707 | 3.15 | 169.0132 |
| M4 | Protocatechuic acid sulfate | C7H6O7S | 2.23 | negative mode | 232.9757 | 2.62 | 153.0183, 109.0295 |
| M5 | 2- | C7H8O6S | 2.35 | negative mode | 218.9963 | 2.31 | 139.0389, 124.0154 |
| M6 | 1- | C7H8O6S | 2.72 | negative mode | 218.9964 | 2.72 | 139.0390, 124.0154 |
| M7 | Methylgallic acid sulfate | C8H8O8S | 2.75 | negative mode | 262.9866 | 3.63 | 183.0291, 168.0055 |
| M8 | Pyrogallol-1- | C6H6O6S | 2.85 | negative mode | 204.9806 | 2.46 | 125.0233 |
| M9 | 2- | C13H16O9 | 3.02 | negative mode | 315.0725 | 4.51 | 139.0401, 124.0166, 113.0245 |
| M10 | 4- | C8H8O5 | 4.04 | negative mode | 183.0291 | 1.64 | 168.0055, 124.0155 |
| M11 | Phenol sulfate | C6H6O4S | 4.08 | negative mode | 172.9905 | 1.24 | 93.0333 |
| M12 | Pyrogallol-1- | C12H14O9 | 4.28 | negative mode | 301.0564 | 3.39 | 125.0232 |
| M13 | Dehydroxylation and ring | C8H8O6S | 4.32 | negative mode | 230.9964 | 2.79 | 187.0063, 151.0393, 107.0490, 79.9560 |
| M14 | 1- | C7H8O6S | 4.74 | negative mode | 218.9968 | 4.82 | 139.0402, 124.0166 |
| M15 | Glucuronidation of 5,7- | C15H14O10 | 5.35 | negative mode | 353.0510 | 2.00 | 177.0183 |
| M16 | C9H8O6S | 5.50 | negative mode | 242.9966 | 3.27 | 163.0392, 119.0493 | |
| M17 | Sulfation of vanillic acid | C8H8O7S | 5.63 | negative mode | 246.9914 | 2.92 | 167.0340, 152.0107, |
| M18 | Ethyl gallate glucuronide | C15H18O11 | 5.67 | negative mode | 373.0775 | 2.61 | 197.0448, 169.0144, 125.0233 |
| M19 | Syringic acid glucuronide | C15H18O11 | 5.94 | negative mode | 373.0775 | 2.61 | 197.0447, 182.0208, 166.9976 |
| M20 | 3,4- | C9H10O8S | 6.20 | negative mode | 277.0022 | 3.49 | 197.0449, 182.0213, 166.9977 |
| M21 | 5-(3′,4′-Hydroxyphenyl)- | C17H20O10 | 6.46 | negative mode | 383.0979 | 1.64 | no fragment |
| M22 | Methylcatechin glucuronide | C22H24O12 | 6.64 | negative mode | 479.1188 | 0.91 | 465.1025, 303.0863 |
| M23 | Urolithin A glucuronide-sulfate diconjugate | C19H16O13S | 6.74 | negative mode | 483.0233 | 1.10 | 403.0664, 227.0346 |
| M24 | 3- | C14H16O11 | 6.81 | negative mode | 359.0617 | 2.29 | 183.0293, 168.0068, 124.0154 |
| M25 | 5-(3′,4′-Dihydroxyphenyl)-γ-valerolactone sulfate | C11H12O7S | 6.88 | negative mode | 287.0233 | 4.35 | 207.0504, 163.0764, 79.9574 |
| M26 | Syringic acid-4- | C9H10O8S | 7.02 | negative mode | 277.0021 | 3.16 | 197.0454, 182.0213, 166.9976 |
| M27 | Quercitrin glucuronide | C27H28O17 | 7.20 | negative mode | 623.1252 | 1.55 | 447.0935 |
| M28 | Sulfation of 5,7- | C9H6O7S | 7.41 | negative mode | 256.9760 | 3.85 | 177.0186, 133.0284 |
| M29 | Trihydroxyflavanone glucuronide | C22H20O12 | 7.60 | negative mode | 463.0884 | 2.76 | 287.0561 |
| M30 | 5-(3′-Hydroxyphenyl)-γ- | C11H12O6S | 8.09 | negative mode | 271.0280 | 3.19 | 191.0706, 147.0820 |
| M31 | Isolariciresinol-4 (or 4′)- | C26H32O12 | 8.39 | negative mode | 535.1819 | 1.64 | 359.1497, 344.1266, 329.1036, 241.0507 |
| M32 | Isolariciresinol-4 (or 4′)- | C26H32O12 | 8.55 | negative mode | 535.1822 | 2.21 | 359.1498, 344.1259 |
| M33 | Glucuronidation of 3,5′-dimethoxy-isolariciresinol | C28H36O14 | 8.72 | negative mode | 595.2025 | -0.07 | 419.1709, 404.1469 |
| M34 | Urolithin C glucuronide | C19H16O11 | 9.47 | negative mode | 419.0620 | 2.61 | 243.0300 |
| M35 | Isolariciresinol-9 (or 9′)- | C26H32O12 | 9.65 | negative mode | 535.1821 | 2.00 | 359.1498 |
| M36 | Isolariciresinol-9 (or 9′)- | C26H32O12 | 9.86 | negative mode | 535.1823 | 2.44 | 359.1504, 344.1267, 329.1029, 241.0507 |
| M37 | Sulfation of Isolariciresinol | C20H24O9S | 10.00 | negative mode | 439.1073 | 2.19 | 359.1497 |
| M38 | Urolithin A glucuronide | C19H16O10 | 10.13 | negative mode | 403.0669 | 2.20 | 227.0345, 199.0388, 183.0446, 175.0239, 155.0491 |
| M39 | Quercetin diglucuronide | C27H26O19 | 11.42 | negative mode | 653.0994 | 0.98 | 447.0671, 301.0345 |
| M40 | Urolithin C sulfate | C13H8O8S | 12.80 | negative mode | 322.9865 | 2.87 | 243.0297 |
| M41 | 3- | C22H20O16S | 13.07 | negative mode | 571.0396 | 1.57 | 491.0832, 315.0511, 300.0275, 148.0155 |
| M42 | Urolithin A sulfate | C13H8O7S | 13.60 | negative mode | 306.9917 | 1.03 | 227.0346, 199.0398, 183.0444 |
| M43 | 3,3′-Di- | C22H18O14 | 13.95 | negative mode | 505.0623 | 2.10 | 329.0303, 314.0048, 298.9833, 270.9883 |
| M44 | Kaempferol glucuronide | C21H18O12 | 15.11 | negative mode | 461.0726 | 2.42 | 285.0402, 255.0293 |
| M45 | Methylation of Ellagic acid | C15H8O8 | 15.82 | negative mode | 315.0146 | 3.35 | 299.9910 |
| M46 | Naringenin glucuronide | C21H20O11 | 15.82 | negative mode | 447.0934 | 1.22 | 271.0612 |
| M47 | 3,3′-Di- | C16H10O11S | 16.48 | negative mode | 408.9866 | 1.52 | 329.0304, 314.0062, 298.9833 |
| M48 | Sulfation and loss of 2 × oxygen of catechin | C15H14O6S | 16.86 | negative mode | 321.0436 | 2.73 | 241.0866, 147.0440, 135.0440, 121.0283 |
| M49 | Kaempferol sulfate | C15H10O9S | 17.51 | negative mode | 364.9972 | 2.77 | 285.0403, 255.0294 |
| M50 | Methylquercetin glucuronide | C22H20O13 | 18.03 | negative mode | 491.0829 | 1.78 | 315.0516, 300.0273 |
| M51 | Methylation of Procyanidin B1 or Procyanidin B2 | C31H28O12 | 20.28 | negative mode | 591.1525 | 4.26 | no fragment |
| M52 | Flazin methyl ether | C18H14O4N2 | 20.68 | positive mode | 323.1024 | −0.85 | 263.0814, 206.0837, 180.0806 |
| negative mode | 321.0879 | 2.86 | 259.0511, 217.0766 |
Figure 6The possible metabolic pathways of (epi)catechin (A) and ellagitannins (B) in hyperuricemia rats administered orally with P. capitatum extract.
Figure 7The data processing workflow for identification of chemical ingredients from P. capitatum and its absorbed constituents in hyperuricemia rat plasma.